John G Ullman & Associates Inc. Sells 69,465 Shares of Bristol-Myers Squibb (NYSE:BMY)

John G Ullman & Associates Inc. cut its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 30.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 158,350 shares of the biopharmaceutical company's stock after selling 69,465 shares during the quarter. Bristol-Myers Squibb makes up about 1.2% of John G Ullman & Associates Inc.'s holdings, making the stock its 22nd biggest position. John G Ullman & Associates Inc.'s holdings in Bristol-Myers Squibb were worth $8,193,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Landscape Capital Management L.L.C. purchased a new position in Bristol-Myers Squibb during the third quarter worth about $319,000. Pzena Investment Management LLC raised its position in Bristol-Myers Squibb by 0.5% in the third quarter. Pzena Investment Management LLC now owns 14,201,746 shares of the biopharmaceutical company's stock worth $734,798,000 after acquiring an additional 67,409 shares during the period. Darwin Wealth Management LLC bought a new stake in Bristol-Myers Squibb in the third quarter worth about $29,000. Portfolio Design Labs LLC bought a new stake in Bristol-Myers Squibb in the third quarter worth about $1,951,000. Finally, First Horizon Advisors Inc. raised its position in Bristol-Myers Squibb by 281.0% in the third quarter. First Horizon Advisors Inc. now owns 395,386 shares of the biopharmaceutical company's stock worth $20,457,000 after acquiring an additional 291,613 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Up 0.6 %

Shares of Bristol-Myers Squibb stock traded up $0.35 during trading on Thursday, reaching $58.23. The company's stock had a trading volume of 7,412,206 shares, compared to its average volume of 14,395,206. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08. The firm's 50-day moving average is $53.26 and its two-hundred day moving average is $47.54. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion during the quarter, compared to analysts' expectations of $11.26 billion. During the same quarter in the prior year, the company earned $2.00 EPS. The firm's revenue was up 8.4% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a $0.60 dividend. The ex-dividend date was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.12%. Bristol-Myers Squibb's dividend payout ratio (DPR) is -66.85%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company's stock, valued at $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Samit Hirawat purchased 1,830 shares of the company's stock in a transaction on Friday, November 1st. The shares were purchased at an average cost of $54.67 per share, with a total value of $100,046.10. Following the transaction, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on BMY shares. Leerink Partnrs raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, November 12th. Daiwa America raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Morgan Stanley lifted their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a research report on Tuesday, November 12th. BMO Capital Markets boosted their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a "market perform" rating in a research report on Tuesday, November 12th. Finally, TD Cowen boosted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $54.07.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.